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Letters to the Editorassessed the late remote ischemic pre-
conditioning (RIPC) in 22 children
who underwent cardiac surgery with
cardiopulmonary bypass. The authors
concluded that ‘‘late remote ischemic
preconditioning did not provide clini-
cally relevant cardioprotection to chil-
dren undergoing cardiopulmonary
bypass.’’ A few comments seem to be
appropriate. It appears that at least 5
children in their RIPC group had cya-
notic heart disease (Taussig-Bing
anomaly, tricuspid atresia, and tetral-
ogyofFallot). Inasmuch as the2groups
in this study appear comparable, the
children with cyanotic heart disease
have chronic hypoxia before surgery.
Is it possible to further precondition
the patients with chronic hypoxia by
brief intermittent episodes of limb is-
chemia induced before surgery? This
question remains to be answered.
My colleagues and I2 have previ-
ously demonstrated in a randomized
controlled trial a clinically relevant
beneficial effect of theRIPC in children
who underwent preconditioning imme-
diately before surgery. Pavione and col-
leagues used the sameRIPC stimulus to
assess a late phase of protection. We3,4
have previously demonstrated that the
RIPC modifies gene expression both
early and late in human blood and in
the myocardium of the experimental
animals. Furthermore, it appears that
intraoperative ischemia–reperfusion
itself induces an early myocardial
gene expression in the children
undergoing heart surgery.5 Thus, both
intermittent preoperative (ie, RIPC)
and prolonged intraoperative ische-
mia–reperfusion induce changes at the
genomic level. One would expect that
chronic hypoxia of the cyanotic heart
disease does the same. Do these geno-
mic changes translate into proteomic
response? This is yet unknown. Our re-
cent, yet unpublished, randomized con-
trolled trial performed in 40 children
undergoing surgery for tetralogy ofFal-
lot indicated that the myocardial phos-
phorylated protein signaling is already
activated in children with chronic hyp-
oxia. Thus, regardless of whether the614 The Journal of Thoracic and CRIPC-induced activation of gene ex-
pression translates into proteomic re-
sponse or not, its clinical effect may
be lost in children with cyanotic heart
disease.
I commend Pavione and col-
leagues on their interesting study
and look forward to seeing whether
the RIPC will find a clinical applica-
tion in children undergoing heart
surgery. Time will show. At the
meantime, the researchers should be
cautioned against including patients
with chronic hypoxia into the trials
inasmuch as chronic hypoxia may
mask the effects of the ischemic
preconditioning.
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We thank Dr Konstantinov1 for his
interesting comments on our article.2ardiovascular Surgery c February 2013We do not, however, believe that the
presence of patients with cyanotic
heart disease in the group undergoing
remote ischemic preconditioning
(RIPC) in our study may have masked
the effects of the ischemic stimulus,
because there were actually 9 patients
with cyanotic heart defects in the
RIPC group (75%) and 6 in the con-
trol group (60%; P ¼ .65). In addi-
tion, preoperative oxygen saturations
were similar in the RIPC and control
groups (mean  SD, 89%  11% vs
89%  7%, respectively; P ¼ .84).
We emphasize that studies performed
in adults undergoing coronary artery
bypass surgery3 and in infants with
ventricular septal defect,4 in which
cases chronic hypoxia would not be
a confounding factor, also failed to
demonstrate any clinically significant
effect of RIPC. Moreover, the useful-
ness of RIPCwould bemost important
in patients at high risk of postopera-
tive complications, such as those in-
cluded in our study. Nevertheless,
many infants with complex congenital
heart disease have some degree of pre-
operative cyanosis. Considering that
RIPC is an innocuous, inexpensive,
and simple procedure, we hoped that
it would decrease inflammation and
postoperative morbidity. Unfortu-
nately, we did not observe these ef-
fects. It thus seems evident that
RIPC with brief periods of limb occlu-
sion, as currently performed, lacks
clinical applicability in patients un-
dergoing heart surgery with cardio-
pulmonary bypass.
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To the Editor:
Enthusiasm and use of transcatheter
aortic valve implantation (TAVI) have
grown exponentially since the first
TAVI procedure was performed a de-
cade ago. Critics of this relatively
novel technique, however, argue that
clinical practice has far outpaced ro-
bust clinical evidence. The recent
summary by Agnihotri1 provides
a broad overview of the recent consen-
sus statement approved by a dozen
professional societies, including the
American Association for Thoracic
Surgery. Agnihotri1 correctly empha-
sizes the subjectivity of the patient se-
lection process for TAVI and a number
of postprocedural complications such
as stroke, requirement for permanentFIGURE 1. Spectrum of patients with severe aortic s
aortic valve implantation.
The Journalpacemaker, vascular injury, and se-
vere aortic regurgitation, all of which
are significantly more likely to occur
than after conventional surgical aortic
valve replacement (AVR). Agnihotri1
also stated, ‘‘There is limited informa-
tion regarding durability beyond 5
years in registry data.’’ One should
also point out there are no published
comparative data between TAVI and
surgical AVR beyond 5 years in the
current literature.
Fromanevidence-basedperspective,
level I evidencehasonlybeenpresented
from 2 randomized controlled trials.
The better known of these, the PART-
NER (Placement of Aortic Transcath-
eter Valve) trial financed by Edwards
Lifesciences (Irvine, Calif), involved
patients who were either deemed to be
at ‘‘high surgical risk’’ (cohort A) or
‘‘inoperable’’ (cohort B).2,3 Recently,
Van Brabandt and colleagues4 high-
lighted the significant ethical, scientific,
and industry-related challenges to the
PARTNER trial related to publication
bias, lack of data transparency, unbal-
anced patient characteristics, and in-
completely declared conflicts of
interest.4 The lesser known STAC-
CATO trial, whichwas not cited byAg-
nihotri1 or the consensus statement,
included patients who were considered
to have ‘‘low surgical risk.’’ This trial
was prematurely terminated by a data
safetymonitoring board after unexpect-
edly poor results for patients in the
TAVI arm.5 The chief investigator of
the STACCATO trial stated that TAVI
should not be considered in patients
who are at a low surgical risk because
of the excellent and established out-
comes offered by surgical AVR.tenosis according to surgical risk for conventional aor
of Thoracic and Cardiovascular SurgeIn summary, patients with severe
aortic stenosis should be considered
in three subgroups, according to their
surgical risk with conventional AVR,
as illustrated in Figure 1. Results
from randomized, controlled trials
suggest that ‘‘inoperable’’ patients
may benefit from TAVI in terms of
mortality and symptomatic outcomes,
although at the cost of increased
stroke risk. The evidence for ‘‘high
surgical risk’’ patients is limited by
short-term follow-up, and existing
data suggest a higher risk of stroke
or transient ischemic attack than that
associated with conventional AVR
without any significant all-cause mor-
tality benefit. With respect to ‘‘low
surgical risk’’ patients, the STAC-
CATO trial has shown that TAVI
should not be offered to these patients
in the current clinical setting. Finally,
there is a fourth recognized subgroup
of patients who are considered to be
at too high a risk for any form of inter-
ventional treatment.2,3
In the future, the development of
novel devices should also be comple-
mented by the development of stan-
dardized, stringent patient selection
processes to allow meaningful com-
parison of outcomes between institu-
tions. On the basis of the available
evidence, the use of TAVI for eligible
surgical candidates should only be
considered within clinical trials or
registries.6
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